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Despite advances in surgery and adjuvant regimes, gastrointestinal malignancy remains a major cause of neoplastic mortality.
Immunotherapy is an emerging and now successful treatment modality for numerous cancers that relies on the manipulation of the
immune system and its effector functions to eradicate tumour cells. The discovery that the pan-epithelial homotypic cell adhesion
molecule EpCAM is differentially expressed on gastrointestinal tumours has made this a viable target for immunotherapy. Clinical
trials using naked anti EpCAM antibody, immunoconjugates, anti-idiotypic and dendritic cell vaccines have met variable success. The
murine IgG2a Edrecolomab was shown to reduce mortality and morbidity at a level slightly lower than treatment with 5FU and
Levamisole when administered to patients with advanced colorectal carcinoma in a large randomised controlled trial. Fully human and
trifunctional antibodies that specifically recruit CD3-positive lymphocytes are now being tested clinically in the treatment of minimal
residual disease and ascites. Although clinical trials are in their infancy, the future may bring forth an EpCAM mediated approach for
the effective activation and harnessing of the immune system to destroy a pathological aberrance that has otherwise largely escaped
its attention.
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Gastrointestinal malignancy remains one of the largest causes of
neoplastic mortality and morbidity. The use of immunotherapy to
target tumours is well established. This combines antibodies that
specifically target antigens selectively expressed on tumour cells
and cytotoxic effector mechanisms. Successful clinical use includes
the treatment of breast cancer by HER-2-specific trastuzumab
(Goldenberg, 1999), follicular non-Hodgkin B-cell lymphoma by
CD20 specific rituximab (Hainsworth, 2000).
Immunotherapeutic strategies for abdominal malignancy in-
clude targeting of the cell-adhesion molecule EpCAM. This article
reviews the expression and function of EpCAM in normal and
neoplastic tissue. The variety of strategies to target EpCAM are
discussed, followed by a review of their use in clinical trials to
target GI malignancy.
EPCAM BIOLOGY
Structure and function
EpCAM is a pan-epithelial differentiation antigen expressed on
the basolateral surface of all carcinomas to varying degrees. As a
homotypic cell adhesion molecule, it is intimately integrated within
the Cadherin–Catenin and WNT pathways. It has recently been
shown to modulate the expression of proto-oncogenes such as c-myc.
Tissue morphogenesis EpCAM is essential for stable adhesion
formation and tissue morphogenesis similar to adhesion mole-
cules: carcino-embryonic antigen and ICAM-1. The precise
mechanism by which cytoskeletal and intracellular elements
mediate this function are being characterised. EpCAM inhibits
intercellular adhesion mediated by cadherins (Litvinov et al, 1997)
E-cadherin in turn interacts with a-, b- and g-catenins forming the
cadherin–catenin complex (Figure 1).
Catenins link cadherins with the actin cytoskeleton and form
complexes with other proteins. Cadherins are crucial for the
establishment and maintenance of epithelial cell polarity, mor-
phogenesis of epithelial tissues and regulation of cell proliferation
and apoptosis. Their association with b-catenin is particularly
interesting as this is a component in the WNT pathway that
regulates the expression of proto-oncogenes, such as c-myc:
fundamentally associated with tumour development. Wnt glyco-
proteins are signalling molecules that regulate cell-to-cell interac-
tion during embryogenesis. Wnt proteins bind to receptors of the
Frizzled family. Through several cytoplasmic relay components,
the signal is transduced to b-catenin, which is stabilised,
accumulates in the cytoplasm, and enters the nucleus, where it
binds a lymphoid enhancer factor/T-cell factor transcription
factor. Together, b-catenin and lymphoid enhancer factor/T-cell
factor activate expression of many target genes, such as c-Myc,
VEGF, cyclooxygenase-2, all associated with neoplasia.
EpCAM directly impacts the cell cycle by upregulating c-myc and
cyclin A/E. Human epithelial cells expressing EpCAM reduce growth
factors dependency, and increase metabolism and colony formation.
Inhibition of EpCAM expression with antisense mRNA reduces
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www.bjcancer.comproliferation and metabolism in human carcinoma cells. The
intracellular domain is essential for these effects (Munz et al, 2004).
EpCAM’s adhesive properties promote calcium-independent
homotypic cell sorting. Cells transfected to express EpCAM are
sorted from cells of the same line that do not normally express
EpCAM (Litvinov et al, 1994). It also inhibits invasive growth in
cell colonies. Both activities are inhibited by anti-EpCAM
antibodies (Litvinov et al, 1994).
Pattern of tissue expression in the GI tract
Normal tissue EpCAM is present in all normal epithelia excluding
stratified squamous epithelia. Within the GI tract, colonic expression
is the greatest and gastric the lowest. Glandular GI epithelium displays
a marked expression gradient from crypts to the apex of villae.
Abnormal tissue Carcinomas and actively proliferating tissues
show that increased and differential expression of EpCAM.
Expression correlates with differentiation in gastric lesions.
Immunochemical and mRNA studies show well-differentiated
tumours are more expressive than those less differentiated. Normal
background mucosa shows weak expression but, interestingly,
areas of Barretts oesophagus or metaplasia are highly expressive
(Litivinov, 1996; Wong, 2006).
90% of Colorectal carcinoma cells express EpCAM but in a
differential form. Modifications include variable glycosylation
analogous to tumour-specific antigens such as colonic tumour
antigen MUC-1 (Denda-Nagai and Irimura, 2000). EpCAM exists
in the cell membrane of colon carcinoma cells as a high-affinity
noncovalent cis-dimer. Dimers on opposing membranes can
associate via a head-to-head interaction to form tetramers with
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Figure 1 EpCAM domains and possible association of EpCAM with the Wnt pathway (modified from Huelsken and Behrens, 2002). EpCAM structure:
extracellular, transmembrane and intracellular components are shown. The extracellular component contains three domains: the first is novel and is the
site to which most of the antibodies developed are targeted (323/A3, 17-1A and others). The second is similar to EGF-binding proteins 1 and 6 and
thyroglobulin. The third also has a novel structure that also has similarities with EGF. The intracellular portion of the antigen has a tyrosine phosphorylation
site, the exact significance of which is uncertain.
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tions. It is not known how exactly antibody binding correlates with
variable glycosylation or oligomerisation in a functional or
structural sense, and further investigation is required.
Tissue microarray studies allow comprehensive assessment of
the tumour expression of EpCAM. A recent study compared 3900
tissues of tumour of stratified stages and grades of 134 different
histological subtypes sourced from head and neck, lung, gastro-
intestinal, breast, urogenital and mesenchymal tumours. Seventy-
five per cent tumour categories expressed EpCAM. At least weak
EpCAM expression in 410% of tumours was observed in 87 of
131 different tumour categories. Colonic (81%), gastric, pancreatic
(78%) and lung carcinomas revealed a high proportion of strongly
positive tumours, suggesting EpCAM is an attractive target for
pan-carcinoma immunotherapy (Went et al, 2004).
Paradox of expression with advance in carcinomas
The functionally paradoxical upregulation of EpCAM with disease
progression in colorectal, breast, prostate and upper GI carcinomas
(Pocztek 1999; Gastl et al, 2000) remains unexplained. This is
intriguing in metastatic carcinoma in which degradation of
intercellular adhesions is a primary feature. Perhaps, EpCAM is
upregulated in response to other intra-and extracellular processes
that promote destruction of tissue adhesion and morphology,
maintaining its constitutional stabilising function. Although this
has not been investigated specifically, loss of EpCAM expression is
clearly associated with increased local recurrence risk in patients
with colorectal cancer (CRC) (Kapiteijn, 2002). In a study looking at
resection specimens, loss of EpCAM was significantly associated with
a diffusely infiltrative morphology but not with distant recurrence.
The relative loss of EpCAM expression in patients with gastric
cancer is associated with a significant reduction in survival,
indicating that loss of EpCAM expression identifies aggressive
tumours especially in patients with stage I and II disease. Data
from a Dutch study compared p53, CD44, E-cadherin, EpCAM and
c-erB2/neu in tumours of 300 patients, investigating the extent of
lymph node clearance. Patients without loss of EpCAM expression
of tumour cells (19%) had a significantly better 10-year survival
compared with patients with any loss: 42 vs 22%. The prognostic
value was stronger in stages I and II, and independent of the TNM
stage (Songun et al, 2005).
This presents yet another paradox suggesting that, once
neoplastic transformation has taken place, a reduced EpCAM
expression is an indicator of a more aggressive tumour phenotype
with increased invasion, metastasis and mortality. This seemingly
contradicts a recent study that suggested EpCAM silencing leads to
reduced invasive potential of tumour cells. Breast cancer cell-lines
were grown in Matrigel invasion/migration chambers. Cells in
which EpCAM expression was silenced with SiRNAs showed a
reduction of 35–80% in proliferation, 92% in cell-migration and
96% in cell-invasion without increase in cell death or apoptosis.
There was, however, an increase in E-cadherin, a-catenin and
b-catenin. This may be due to silencing of the inhibition that
EpCAM exerts on E-cadherin. Alternatively, EpCAM gene silencing
may lead to decreased cytoplasmic b-catenin through an increase
in its association with the E-cadherin adhesion complex. Hence,
reducing EpCAM may decrease b-catenin availability for the wnt
pathway and activation of its target genes downstream (Osta et al,
2004).
We postulate that EpCAM expression increases up to a point
after which destabilising factors predominate and its expression is
no longer stimulated. Once this point is reached, which may be
variable according to the particular tumour type, tumours are less
stable and display greater invasive and metastatic potential. A
comprehensive study of the temporal expression of EpCAM during
tumour progression is currently lacking. This would be useful as a
predictor of the efficacy of immunotherapy in individual patients
according to their tumour stage.
Interestingly, a recent study revealed a 10-fold reduction in the
expression of EpCAM in circulating tumour cells compared with
primary tumours from whence they emerged and established
metastases. (Rao, 2005). We postulate that the absence of
homotypic adhesions in the vascular microenvironment may be
the causal link. Indeed, EpCAM-targeted immunotherapy may be
more effective in the context of established tumours or metastases
as opposed to fluid-borne disease. This does not preclude ascites
due to peritoneal metastases for which treatment with trifunctional
antibodies is effective. However, the efficacy of destroying blood-
borne circulating tumour cells in a hope of eradicating minimal
residual disease may be limited.
EPCAM TARGETED IMMUNOTHERAPY
Immunotherapy manipulates competent host immune system
inducing tumour growth inhibition, regression or cytolysis.
Approaches include the use of monoclonal antibodies and their
derivatives, hybrid bispecific (trifunctional) antibodies, tumour
cell vaccines, anti-idiotypic antibodies and dendritic cell vaccines.
Pure immunomodulatory cytokines have been used to enhance the
effect of monoclonal antibodies (MAbs).
Mechanism of tumour inhibition
The mechanisms by which anti-EpCAM antibodies exert tumour
inhibition in vivo remain controversial. Cytotoxic mechanisms
include antibody dependent cell cytotoxicity (ADCC) mediated by
natural killer cells and T lymphocytes, complement mediated
cytolysis (CMC) and opsonisation promoting phagocytosis
mediated by PMNs.
The question of whether anti-EpCAM antibodies directly inhibit
tumour cell proliferation remains unanswered. It could be
postulated that EpCAM antibodies directly interfere with the
activation of the Wnt pathway causing downregulation of c-myc:
this remains untested. The majority of anti-EpCAM antibodies
produced are specific for epitopes within the first of two EGF-like
domains in the extracellular segment of EpCAM (Figure 1), and
none have been shown to mimic the dimerisation/tetramerisation
that EpCAM undergoes on ligation or to interfere with downstream
gene activation or cell proliferation in vivo. EpCAM antibodies do
obliterate EpCAM mediated homotypic cell-sorting activity in vitro;
this effect may be a competitive event preventing dimerisation
alone. Although it is unlikely that a similar competitive effect takes
place in established tumours, an investigation to see any effect on
the establishment of metastases would be interesting.
We still await a comparison between the differences in the toxicity
of antibodies according to the functional EpCAM domain targeted.
It is possible that the majority of these antibodies work to opsonise
cells alone – inducing the cytolytic mechanisms mentioned above –
particularly as no physiological ligands for the extracellular domain
of EpCAM other than EpCAM itself have been identified.
EpCAM has recently been found to form a complex with the
tight junction protein Claudin-7 within its intra membranous
segment. The physiological significance of this is not yet known,
although an effect on apoptosis resistance in tumours is intriguing.
A flurry of interest followed the assertion that LAIR-1, a member
of the inhibitory group of the immunoglobulin-like receptors, was
a novel receptor for EpCAM. Speculation arose that neoplastic cells
escape immunological surveillance and clearance by interacting
with LAIR-1 via EpCAM gaining selective advantage for their
growth, spread and dissemination. This seemingly attractive
hypothesis was nullified when the original paper by Meyaard
et al. was retracted because the observed binding of the LAIR-1 to
EpCAM transfected cells was an artefact, attributed to the
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anti-human EpCAM monoclonal antibody.
Mechanism of ADCC Both the direct antigen binding portion Fab
and constant Fc regions of antibodies contribute to their activity.
Fab portions bind to specific epitopes of target antigens whereas
the Fc portion associates with immune effector cells to mediate
ADCC, phagocytosis, endocytosis, release of inflammatory cyto-
kines and antigen presentation. Both natural killer cells and
monocytes express the FC receptor: FcgRIII also known as CD16
(Eccles, 2001).
Mice lacking activation Fc receptors (FcgRI-CD64 and gRIII-
CD16) show substantially reduced responses to antitumour MAbs.
In contrast, mice deficient in the inhibitory receptor FcgRIIb-CD32
respond to the same antibodies with enhanced ADCC and tumour
growth inhibition. Engineering the Fc portion to maximise FcgRIII
binding may enhance the therapeutic benefit of immunotherapeu-
tic agents. The significance in human context remains unknown
(Clynes et al, 2000).
Clinical trials (Table 1)
Monospecific murine antibody The murine Ig2a anti-human 17-
1A monoclonal antibody: Ederecolomab was the first immunother-
apeutic agent licensed for use in large-scale human anti-tumour
immunotherapy trials. Initial trials in patients with advanced CRC
showed little improvement in morbidity or mortality. Augmenta-
tion with IFN and GM-CSF increased ADCC with associated
tumour lymphocyte infiltration and complement deposition.
Patients with greater ADCC survived longer.
In 1994, 189 patients with Dukes C CRC were randomly assigned
to adjuvant therapy with Ederocolomab or resection alone.
Survival at 3 years was 72% for the Ederocolomab cohort and
62% for surgery alone. Further follow-up at 7 years showed
significantly reduced mortality (32%), disease recurrence (23%)
and metastases leading to further phase II and III trials.
In 2002, Punt published results of a trial of 2761 patients
randomised to MAb 17-1A monotherapy, 5-FU and Folinic-acid or
5-FUþEderocolomab. No additional benefit was seen by adding
immunotherapy to the standard chemotherapy regimen at 26
months. Immunotherapy alone was associated with significantly
shorter disease-free survival; ederecolomab was removed from
circulation.
The discrepancy between preclinical and clinical findings has led
to much debate. What are the reasons for this discrepancy?
EpCAM expression density varies at different stages of tumour
growth suggesting that patient antigen positivity should be
assessed before clinical use. EpCAM density is a proven predictor
of survival in breast cancer patients (Gastl et al, 2000).
As a murine antibody, Ederecolomab induces a neutralising
humoural response in humans resulting in a short serum half-life.
Foreign MAbs are rapidly cleared as immune complexes deposit-
ing in the liver, greatly reducing bioavailability. Reduced compat-
ibility with human effector cells may also be significant (Pimm and
Gribben, 1993).
EpCAM targeted immunotherapy to date has targeted advanced
disease: its value weighed against classic adjuvant treatments. The
effect of such immunotherapy on earlier, less established disease or
cancer models is unknown.
What are the solutions?
Table 1 Trials to assess efficacy of EpCAM targeted Immunotherapy for intra-abdominal carcinomas
Author Patients Treatment Results Conclusions
Weiner et al
(1986)
27
Metastatic adeno
carcinoma Colon or
Pancreas
Passive
MAb17-1A preceded by 4 days
gIFN
No objective clinical markers
Serum tumour markers reduced in 36% 11
developed Ab3 response
MAb 17-1A safe for clinical use
Evidence of anti-idiotypic response
Herlyn et al (1994) 9
CRC
Active
Anti-Idiotypic CO17-1A Aluminium
hydroxide precipitated
3 patients developed Ab3 response to Ab2
determinants
Marginal success
Herlyn et al (1994) 54
CRC
Active
Polyclonal goat and monoclonal Rat
anti-idiotypic CO17-1A
Majority developed Ab3 response 30%
developed delayed type hypersensitivity
Anti-idiotypic CO17-1A effective in
stimulating log-term immunity in cohort
Fagerberg et al
(1995)
6
CRC
Active
Anti-Idiotypic CO17-1A
6 patients developed T-cell immunity
5 mounted Ab3 response
Small study
Evidence of anti-idiotypic response
Ragnhammar et al
(1995)
86
Adv CRC
Passive
Murine MAb17-1A (76) or
chimeric MAb17-1A (10)
All patients developed anti-idiotypic Abs
Increased by GM-CSF; c-MAb less response
and more allergic side effects than MAb
Patients with Ab2 response – median
survival 9/12
Riethmuller et al
(1998)
189
Dukes C
Passive observation or MAb17-1A
Adjuvant
7 year evaluation, mortality decreased by
32% and recurrence by 23%
Therapeutic effect maintained after 7
years, mortality/recurrence reduced
Shetye et al (1998) 20
Adv CRC
Passive single infusion
MAb17-1A+ GM-CSF
Increased tumoural and PMN, monocytes
and T lymphocytes
Increased TILs representing ADCC and
CTLs
Hjelm et al (1999) 20
Adv CRC
Passive
MAb17-1A+IL-2+GM-CSF
1 patient partial remission 2 patients stable
disease for 7 and 4 months
No augmentation of effect of MAb 17-
1A
Punt et al (2002) 2761st III CRC Passive
Multicentre;
(1) 17-1A MAb/5FU/LV or
(2) 5 FU/LV or
(3) 17-1A MAb
3-yr surv DFS
(1) 74.7% 63.8%
(2) 76.1% 65.5%
(3) 70.1% 53.0%
Addition of Ederocolomab to standard
therapy does not improve the disease
outcome
Panorex withdrawn
TRION Pharma,
Fresenius 2003
23
symptomaticascites
Ca Ovary
Passive trifunctional
Multicentre open label
intraperitoneal Removab
Well-tolerated 22 of 23 patients ascites
free at day 37
Effective treatment of malignant ascites
Phase III for all-cause malignant ascites
underway
Heiss 2005 8
Peritoneal
carcinomatosis
Passive Trifunctional
4-6 applications Intraperitoneal
7 of 8 patients no further paracentesis
needed.
Eradication of tumour cells in ascites
ADCC¼antibody-dependant cell cytotoxicity; CRC¼colorectal cancer; CTL¼cytotoxic T cells; DFS¼disease-free survival; GM-CSF¼granulocyte-macrophage-colony
stimulating factor; IFN¼interferon; MAB¼monoclonal antibody; PMN¼polymorphonuclear cells; TIL¼tumour infiltrating lymphocytes.
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combines binding affinity similar to Ederecolomab with consider-
ably enhanced ADCC potency with human gastric carcinoma cell
lines. Addition of human serum containing IgG or human
peripheral blood monocytes halves MT201 ADCC but abolishes
that of Ederecolomab: indicating the importance of human anti-
mouse antibodies (HAMA) and compatibility of syngeneic effector
cells (Naundorf et al, 2002).
MT201 reduces tumour growth in xenotransplanted HT-29 CRC
cells in nude mice but only to a level similar to Ederecolomab. As
any athymic model is deficient in effector cells, its utility in
assessing effector responses comparing antibody type is limited. It
is hoped human effector cells with greater type specificity of FCg
receptors will facilitate amplified tumour inhibition clinically.
Trials are underway.
Anti-idiotypic antibodies Active immunotherapies triggering spe-
cific T cells are being assessed. Strategies based on the administra-
tion of EpCAM antigen provided as DNA of the whole protein, or
class I-HLA-binding peptides pulsed on DC or combined to
adjuvants are also under investigation at preclinical or clinical level.
Anti-idiotypic antibodies attempt to stimulate a prolonged,
active immune response. Immunisation with a primary antigen
such as EpCAM generates anti-EpCAM antibodies termed Ab1.
Anti-idiotypic antibodies are then generated against Ab1. These
antibodies termed Ab2 mimic the tertiary structure of EpCAM.
Ab2 antibodies are used as surrogate immunogens for the
production of Ab3, which are active against the original antigen
EpCAM. Ab2 are endocytosed by APCs and hence represented by
major histocompatibility complex class II antigens to stimulate
CD4þ T helper cells. This occurs in the presence of the co-
stimulatory molecule CD80/86 on APCs interacting with CD28 on
TH cells. These then proliferate and mature to lymphocytes
secreting cytokines Il-2, IFN-g and tumour necrosis factor (TNF)-
a. Il-2 stimulate a humoral and cell-mediated immune response.
The cell-mediated response causes CD8þ Cytotoxic T lympho-
cytes proliferation and subsequently mature under the influence of
IFN-g and TNF-a to mediate cytolysis either by Fas–Fas ligand
interaction to cause apoptosis or by the exocytosis of vesicles
containing perforins and other proteases.
Although the prolonged spectre of active immunity is attractive
in theory, multiple trials assessing the efficacy of anti-idiotypic
antibodies against EpCAM for advanced GI cancer have shown
only marginal success (Table 1).
Among the first was an anti-idiotypic antibody targeted against
the GA733-antigen associated with EpCAM (Co17-1A). Antigen-
specific T-cell immunity was detected in all six patients immunized
(Fagerberg et al, 1995).
Two trials were performed in 1994; the first developed rat anti-
idiopathic antibody to EpCAM. Of nine CRC patients immunised,
only 1 out of 3 developed active Ab3. A further trial assessed
immunisation of 54 CRC patients using polyclonal goat and
monoclonal rat Ab2 targeted against MAb CO17-1A (Ab1)
prepared as alum precipitates. The majority produced Ab3
antibodies sharing epitopes with the corresponding Ab1. One out
of three displayed delayed-type hypersensitivity and specific T
cells that readily proliferated in the presence of antigen in vitro
(Herlyn et al, 1994).
The immunogenicity of full-length EpCAM encoded by recom-
binant vaccinia virus (VV GA733-2) has been assessed in a murine
model. This induces antibodies to previously unknown epitopes
and promotes ADCC of CRC targets with murine macrophages.
Immunized mice developed Ag-specific, proliferative and delayed-
type hypersensitive lymphocytes. The proliferation of ras-trans-
formed syngeneic tumour cells expressing human EpCAM was
suppressed in vivo suggesting the potential of VV GA733-2 as a
candidate vaccine for patients with CRC (Zaloudik et al, 2002).
BISPECIFIC ANTIBODIES
Structure and rationale for development
Normal IgG molecules compose of Fc and FAb segments (Figure 2).
The monospecific FAb segment binds to specific epitopes on
antigens, whereas the Fc portion recruits cells expressing Fc
receptors (e.g. FcgR) such as macrophages. These are described as
being bifunctional and monospecific. In trifunctional antibodies,
the two halves of the FAb segment have different specificity: they
are bispecific and trifunctional.
Both Ederecolomab and MT201 are bifunctional antibodies: IgG1
and IgG2A respectively with active components being the anti-
EpCAM FAb segments and Fc portions. Zeidler (1999) successfully
constructed a bispecific/trifunctional, targeting both EpCAM and CD3
(BiUII or Removab). The rationale being that ADCC is complemented
b yt h ep r e s e n c eo fC D 3þ T-lymphocytes in addition to macrophage/
monocytes, NK and dendritic cells, known to express FcgRb i n d i n gt o
the Fc portion of the antibody. This antibody consists of a Murine
IgG2a associated with an anti-EpCAM FAb segment and Rat IgG2b
associated with anti-CD3 (Lindhofer et al, 1995).
In vitro cytotoxicity
Initial in vitro experiments of ADCC with squamous cell
carcinoma cell lines, effector cells and BiUII demonstrated
increased production of IL-1b, IL-2, IL-6, IL-12 and DC-CK1.
It is postulated that simultaneous stimulation of accessory cells
and T lymphocytes leads to antigen presentation to T-lymphocytes
inducing immunomodulation and cytotoxicity. BiUII induces
production of IL-2 in the presence of EpCAMþ cells activating
CD3 Ep-CAM
Mouse 
IgG2a
Rat 
IgG2b
Tumour cell
ADCC
T- cell
CD40L
CD28
CD2
CD40
B7.1-2
LFA-3
IL-12
IL-2
IL-1
IL-6
DC-CK1
Stimulation
FcRl+ cell
1
2
TNF-
Figure 2 BiUII structure and functional advantage. The Fc portion of
BiUII consisting of murine g2a and rat g2b heavy chains brings together two
molecules that are highly potent activators of FcR similar to human g1. BiUII
has been shown to activate CD3þ lymphocytes, monocytes and
macrophages expressing Fc gRIII, NK cells expressing RI but not B cells
expressing RII-CD32. These heterologous Fc portions were found to be
more potent than the homologous Fc portions of either of the two
parental antibodies used to construct BiUII.
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IL-2. It is thought that an immunologically self-supporting tri-cell
complex is formed, which is efficient for immune cell activation.
Interestingly, computerised sequential video microscopy shows
that cytolysis occurs within 1–3 days, with no difference between
patient and healthy donor PBMCs. The mode of cell death is
characteristically necrotic and not apoptotic. Lymphocytes with
pore-forming perforin proteins surround the tumour cells causing
cytolysis (Riesenberg et al, 2001).
Prolonged antitumour immunity in vivo
Another bispecific antibody BiLu induces long-lasting anti-
tumour immunity when administered intraperitoneally in a murine
syngeneic model (Ruf and Lindhofer, 2001). It targets murine CD3
and human EpCAM. The Fc portion is identical to Removab.
The immunogenic function of BiLu, was investigated in an
elegant study in which melanoma and A20 B-cell lymphoma cells
were transfected with human EpCAM. Effective ADCC in the
presence of BiLu and naı ¨ve spleen cells was greater for BiLu
compared with its monospecific parental antibodies. Melanoma
cells were injected into the peritoneal cavity of immunocompetent
syngeneic mice, whereas B-cell lymphoma cells were introduced
intravenously. Both groups received either intraperitoneal BiLu or
parental antibodies.
All BiLu-treated animals survived; those treated with parental
antibodies had significantly lower survival (100 vs 29%) and all
tumour controls died by day 28. BiLu-treated surviving animals
displayed an IgG2a humoral immune response but no IgG1
response. Nonsurvivors mounted only weak immune responses.
Survivors rechallenged with reduced but potentially lethal doses of
transfected cells established long-lasting immunity, actively
rejecting tumour at day 144.
In a separate experiment irradiated, proliferation-incompetent
transfected A20 cells and BiLu were used as an intraperitoneal
vaccine. Tumour reactive antibodies were found in mice-
administered BiLu but not in controls that had cells alone.
Both CD4þ and CD8þ T lymphocytes are required for the survival
effects of the vaccination, generating humoral cytotoxic responses.
Vaccination with antibody devoid of the Fc portion failed to induce
immunity emphasising the indispensable nature of FcgRIþ cells.
Although BiLu is useful in murine models, its murine anti-CD3
specificity limits its role in human disease. Its counterpart
Removab targets human CD3 and has shown promising results.
Clinical trials
A phase I/II study for the treatment of ovarian cancer patients with
symptomatic ascites has now been completed (23 patients),
showing that Removab was safe and effectively reduced ascitic
flow and tumour-cell content. A substantial phase II/III trial
assessing efficacy in patients with all causes of malignant ascites
including primary gastrointestinal tumours commenced in Sep-
tember 2004 (250 patients), and a Phase IIa study of platinum
refractory ovarian cancer patients is also underway. Finally, a Phase
I/II study of patients with peritoneal carcinomatosis owing to GI
tumours but without symptomatic ascites is underway. Preliminary
results are promising, indicating the utility of Removab in the
treatment of minimal fluid borne disease and micrometastases.
CONCLUSION AND FUTURE CHALLENGES
The discovery of antigens differentially expressed either on the
surface of tumour cells or on part of their metabolic repertoire has
created an opportunity for a new modality of cancer treatment.
The concurrent development of monoclonal antibody technology
has realised the potential of this opportunity.
Immunotherapy has the potential not only to provide magic
bullets that trigger changes in the trajectory of cellular differentia-
tion but also to harness with exquisite specificity the devastating
storm of the immune system to eradicate tumours. Its potential for
a long-lasting memory can also reduce recurrence.
The results of the largest clinical immunotherapy trials targeting
EpCAM highlighted discrepancy between the high level of ADCC
seen in vitro and disease-free survival and mortality. The classic
problems of patient selection, time of therapy, delivery and
specificity require further investigation.
Development of fully human MT201 antibody: currently being
tested in phase I and II trials attempts to optimise delivery by
alleviating HAMA production. Alternative approaches involving
removal of the Fc portion retaining the Fab, F (ab)2 have been
studied but only appear to be useful in vitro.
The functionally intricate role of EpCAM within the WNT pathway
remains largely unexplored and therapeutically unexploited.
The temporal expression of EpCAM in the life cycle of human
gastrointestinal tumours remains largely unstudied. Indeed, there
may be a golden window of opportunity when EpCAM expression
increases to a point after which metastatic tumour cells reduce
expression. Use of EpCAM targeted immunotherapy earlier in
disease progression may enhance tumour penetration and delivery
to target cells in solid tumours.
Until we understand exactly how EpCAM antibodies on cancer
cells, we cannot fully grasp what really happens in vivo and therefore
we can only marginally improve EpCAM-based immunotherapy.
Full structural information correlating the effect of antibodies on
EpCAM structure, function and downstream pathways as well as
gene regulation and proliferation require further research. Although
it is widely held that ADCC is the major mechanism of tumour
inhibition direct antibody effects in vivo cannot be precluded.
Through greater understanding of the Fc/FcR interplay of
antibody and effector cells in cancer patients, it may be possible to
engineer Fc portions of trifunctional antibodies with greater
accessory cells specificity maximising ADCC.
Pre-clinical efficacy of bispecific/trifunctional antibody immuno-
therapy is proven. Utilisation of these exciting new antibodies to
treat human solid carcinomas remains untested. The significance of
human clearance of rodent antibody in the case of Removab
remains unknown.
Clinical trials in this area are in their infancy. Preliminary
results from intraperitoneal treatment of malignant ascites are
promising. Indeed, the future seems exciting and may bring forth
an EpCAM-mediated approach for the effective activation and
harnessing of the immune system to destroy a pathological
aberrance that has otherwise largely escaped attention.
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